Academic literature on the topic 'Zhong yang zheng zhi xue xiao'

In this paper, heavy metal oxide glasses co-doped with erbium and holmium ions have been synthesized. Glass composition, based on the bismuth and germanium oxides, has been selected in terms of high thermal stability (delta T = 125 °C), high refractive index (n = 2.19) and low maximum phonon energy (hvmax = 724 cm-1). Up-conversion luminescence spectra under the 980 nm laser diode excitation have been observed as a result of radiative transitions within the quantum energy level structures of Er3+ and Ho3+ ions. Optimization of rare earth ions content has been conducted, the highest emission intensity in the visible wavelength range has been observed in glass co-doped with molar concentration 0.5 Er2O3 / 0.5 Ho2O3. Full Text: PDF ReferencesF. Zhang, Z. Bi, A. Huang, Z. Xiao, "Visible luminescence properties of Er3+?Pr3+ codoped fluorotellurite glasses", Opt. Materials 41, 112 (2014). CrossRef S. Li, S. Ye, T. Liu, H. Wang, D. Wang, "Enhanced up-conversion emissions in ZnO-LiYbO2:RE3+ (RE = Er or Ho) hybrid phosphors through surface modification", J. All. Comp. 658, 85 (2016). CrossRef J. Fu, X. Zhang, Z. Chao, Z. Li, J. Liao, D. Hou, H. Wen, X. Lu, X. Xie, "Enhanced upconversion luminescence of NaYF4:Yb, Er microprisms via La3+ doping", Opt. Laser Tech. 88, 280 (2017). CrossRef Y. Tian, R. Xu, L. Hu, J. Zhang, "2.7 ?m fluorescence radiative dynamics and energy transfer between Er3+ and Tm3+ ions in fluoride glass under 800 nm and 980 nm excitation", J. Quant. Spec. Rad. Tra. 113, 87 (2012). CrossRef M. Zhang, A. Yang, Y. Peng, B. Zhang, H. Ren, W. Guo, Y. Yang, C. Zhai, Y. Wang, Z. Yang, D. Tang, "Dy3+-doped Ga?Sb?S chalcogenide glasses for mid-infrared lasers", Mat. Res. Bul. 70, 55 (2015). CrossRef G. Yang, T. Li, "Broadband 1.53 ?m emission in Er3+-doped Ga-Bi-Pb-Ge heavy metal oxide glasses", J. Rare Earths 26, 924 (2008). CrossRef Y. Guo, Y. Tian, L. Zhang, L. Hu, J. Zhang, "Erbium doped heavy metal oxide glasses for mid-infrared laser materials", J. Non-Cryst. Solids 377, 119 (2013). CrossRef Z. Hou, Z. Xue, F. Li, M. Wang, X. Hu, S. Wang, "Luminescence and up-conversion mechanism of Er3+/Ho3+ co-doped oxyfluoride tellurite glasses and glass?ceramics", J. All. Comp. 577, 523 (2013). CrossRef X. Li, Q. Nie, S. Dai, T. Xu, L. Lu, X. Zhang, "Energy transfer and frequency upconversion in Ho3+/Yb3+ co-doped bismuth-germanate glasses", J. All. Comp. 454, 510 (2008). CrossRef S.S. Rojas, J.E. De Souza, M.R.B. Andreeta, A.C. Hernandes, "Influence of ceria addition on thermal properties and local structure of bismuth germanate glasses", J. Non-Cryst. Solids 356, 2942 (2010). CrossRef M.S. Ebrahim, Irina, Mid-infrared coherent sources and applications, Springer (2008). CrossRef T. Ragin, J. Zmojda, M. Kochanowicz, P. Miluski, P. Jelen, M. Sitarz, D. Dorosz, "Enhanced mid-infrared 2.7 ?m luminescence in low hydroxide bismuth-germanate glass and optical fiber co-doped with Er3 +/Yb3 + ions", J. Non-Cryst. Solids 457, 169 (2017). CrossRef K. Biswas, A.D. Sontakke, R. Sen, K. Annapurna, "Enhanced 2 ?m broad-band emission and NIR to visible frequency up-conversion from Ho3+/Yb3+ co-doped Bi2O3?GeO2?ZnO glasses", Spectr. Acta. Part A, Mol. Biomol. Spectr. 112, 301-308 (2013). CrossRef R.S. Romaniuk, D. Dorosz, J. Żmojda, M. Kochanowicz, W. Mazerski, "Upconversion luminescence in tellurite glass codoped with Yb3+/Ho3+ ions", Proc. of SPIE 8903, 890307 (2013). CrossRef

Recently, sulfonamides have been shown to be promising electrolyte components due to their high chemical and electrochemical stability in lithium batteries [1, 2]. The electrolyte stability becomes critical when applying high voltage and/or utilizing Ni-rich layered oxides in high energy density lithium-ion batteries. Another approach to successful Ni-rich cathode performance is to develop a stable and effective cathode electrolyte interphase (CEI). Given the success of sultones and sulfates in this regard [3, 4], it is hypothesized that nitrogen analogs, like sulfonamides, could be tailored to provide a similar benefit. Indeed, Yim et al. [5, 6] have shown that N,N,N’,N’-tetraethylsulfamide (TES) forms a CEI on NMC811 that imparts high voltage cycling stability and less cathode corrosion. Our earlier studies of TES with Ni-rich NCA also formed a favorable CEI and these results are the topic of this presentation. Herein, we examine the performance of 0 - 4 wt.% TES in our commercially available, high power INR18650-P28A. These cells contain a composite SiO/graphite anode in addition to a Ni-rich cathode. As shown in Fig 1, TES significantly decreased the impedance of the cathode interface after conditioning compared to the control electrolyte. Thereafter, cells containing up to 2%TES show improved capacity retention during long-term high-rate cycling (+1C/-80W). Part of this success was due to a suppression of resistance growth during cycling by TES. Fast charge cycling (+3C/-2C), however, was moderately impaired with increased TES. Considering the largely reduced impedance of the cathode, fast-charge performance may have suffered due to anode rate limitations. These results will be discussed as well as gas generation, storage performance, and additional rate and cycling tests. [1] Shuting Feng, Mingjun Huang, Jessica R. Lamb, Wenxu Zhang, Ryoichi Tatara, Yirui Zhang, Yun Guang Zhu, Collin F. Perkinson, Jeremiah A. Johnson, Yang Shao-Horn. Chem, 5, 2630-2641 (2019) [2] Weijiang Xue, Mingjun Huang, Yutao Li, Yun Guang Zhu, Rui Gao, Xianghui Xiao, Wenxu Zhang, Sipei Li, Guiyin Xu, Yang Yu, Peng Li, Jeffrey Lopez, Daiwei Yu, Yanhao Dong, Weiwei Fan, Zhe Shi, Rui Xiong, Cheng-Jun Sun, Inhui Hwang, Wah-Keat Lee, Yang Shao-Horn, Jeremiah A. Johnson, Ju Li. Nature Energy, 6, 495-505 (2021) [3] Koji Abe, Manuel Colera, Kei Shimamoto, Masahide Kondo, Kazuhiro Miyoshi. Journal of Electrochemical Society, 161 (6) A863-A870 (2014) [4] Jian Xia, N. N. Sinha, L. P. Chen, J. R. Dahn. Journal of Electrochemical Society, 161 (3) A264-A274 (2014) [5] Kwangeun Jung, Taeeun Yim. Journal of Alloys and Compounds, 834,155155 (2020) [6] Ji Won Kim, Kwangeun Jung, Taeeun Yim. Journal of Mater. Sci & Tech. 86, 70-76 (2021) Figure 1

Abstract Background: Improved risk stratification for non-small cell lung cancer (NSCLC) represents a critical unmet need. A Clinical Laboratory Improvement Amendments (CLIA)-certified, 14-gene, quantitative PCR (qPCR)-based expression assay was found to better stratify mortality risk. The association of molecular risk stratification with other clinicopathological, radiomic, and genetic risk factors have not been fully identified, especially in Chinese NSCLC patients (pts). Methods: We newly recruited 102 early-stage non-squamous NSCLC pts who had undergone complete surgical resection. RNA was extracted from tumor tissue specimens and prospective molecular risk stratification by the 14-gene prognostic assay was performed. Gene mutation status and tumor mutational burden (TMB) were evaluated. Histological sections and clinical records were reviewed for canonical prognostic indicators that have been reported to be associated with lung cancer risk. Results: Of the 102 pts, the mean age was 55 years, 66 (64.7%) were female, and 18 (17.7%) had a smoking history. The majority of pts (84, 82.4%) were stage I, with 1 atypical adenomatous hyperplasia (AAH), 6 adenocarcinomas in situ (AIS), 1 stage II, and 2 stage III. 64 pts were deemed low-risk by molecular testing, 24 were intermediate-risk, and 14 were high-risk. The pts of AAH and AIS were all in the low-risk group. The maximum tumor diameter (MTD) in the high-risk group was the highest. There were no significant differences in age, sex, smoking status, pathologic stage, NCCN risk criteria, micropapillary or solid (MP/S) pattern, or the number of lesions between the three groups. The most common driver mutations were EGFR (65%), TP53 (28%), and RBM10 (13%). The molecular risk stratification had a significant association with TP53 (p = 0.013), TP53 loss of function (LOF, p = 0.01), KRAS (p = 0.011), and APC mutation (p = 0.05), but not with EGFR mutation and co-mutational status. TMB in the low-risk pts was significantly lower than in other pts (p = 0.007). The low-risk pts had lower SUVmax (p = 0.076), significantly lower mean CT value (p = 0.023), and mean enhanced CT value (p = 0.005) compared with others. In the NCCN low-risk pts, 25 were molecular low-risk, 12 were intermediate-risk, and 9 were high-risk. The risk stratification showed a significant association with SUVmax, TP53 mutation, and TMB in the NCCN low-risk pts. Pearson correlation showed the molecular risk score was significantly associated with MTD, TMB, SUVmax, mean CT value, mean enhanced CT value, and max CT value. SUVmax showed the strongest correlation with the risk score. Conclusion: The molecular risk stratification by the 14-gene assay was associated with canonical prognostic indicators, like TP53 LOF, TP53, KRAS, APC mutation, TMB, mean CT value, and mean enhanced CT value. Our study provides more evidence of the clinical utility of the qPCR-based prognostic assay. Citation Format: Naixin Liang, Jianchao Xue, Ming Zhao, Bowen Li, Yadong Wang, Zhicheng Huang, Yankai Xia, Ruirui Li, Zhongxing Bing, Zhibo Zheng, Jianpeng Zhang, Bin Wang, Zhe Feng, Xinyu Liu, Haochen Li, Xiaoqing Yu, Yang Song. Comparison of risk factors to molecular risk stratification in Chinese early-stage non-squamous non-small cell lung cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3312.

Abstract Background: Triple-negative breast cancer (TNBC) is a heterogeneous disease and lacks effective treatment. Our previous study classified TNBCs into four subtypes (luminal androgen receptor [LAR], immunomodulatory [IM], basal-like immune-suppressed [BLIS], mesenchymal-like [MES]) with distinct molecular features. We aimed to assess the efficacy and safety of molecular subtype-derived precision treatment in patients with heavily pretreated metastatic TNBC. Methods: This open-label, phase 2, umbrella trial included patients from four centers in China. Participants were women (aged ≥18 years) with histologically confirmed metastatic TNBC with disease progression after multiple lines of standard chemotherapy. Patients were enrolled into seven parallel arms according to their molecular subtypes: LAR with or without ERBB2 somatic mutation/amplification assigned to arm A (pyrotinib with capecitabine) and arm B (androgen inhibitor included therapy); IM assigned to arm C (anti-PD-1 antibody with nab-paclitaxel); BLIS with or without BRCA1/2 germline mutation assigned to arms D (PARP inhibitor included therapy) and E (anti-VEGFR included therapy); MES without or with PI3K-AKT mutation assigned to arms F (anti-VEGFR included therapy) and G (everolimus with nab-paclitaxel). Bayesian predictive probability was adopted to monitor each arm, which can be terminated independently according to a prespecified futility or efficacy boundary. This trial is registered with ClinicalTrials.gov, NCT03805399. Findings: Between October 18, 2018, and February 11, 2022, we enrolled 141 patients. All patients were heavily pretreated and resistant to six categories of the most common chemotherapeutic agents used in breast cancer treatment, with a median of 3 previous lines of therapies in the metastatic setting (Table 1 and 2). The median follow-up was 18.3 months (IQR 11.7-27.7). A confirmed objective response was achieved in 42 (29.8%, 95% CI 22.4-38.1) of the 141 patients. The median PFS was 3.4 months (95% CI 2.7-4.2), and the median OS was 10.7 months (95% CI 9.0-12.3) (Table 3). Arms A, C, E and G achieved efficacy boundaries, with 3 (75.0%) out of 4 patients in arm A, 20 (43.5%) out of 46 patients in arm C, 13 (28.3%) out of 46 patients in arm E, and 3 (33.3%) out of 9 patients in arm G achieving objective responses. Potential predictive biomarkers of efficacy in each arm were explored. Safety data were consistent with the known safety profiles of relevant drugs. Interpretation: We demonstrate the feasibility and clinical utility of a subtyping-based, genomic sequencing-guided strategy which allows the majority of heavily pretreated metastatic TNBCs to benefit from precision treatment. Most arms exhibit promising efficacy and manageable toxicities, providing subtyping schema to optimize personalized treatment. Table 1. The FUTURE trial schema. Patients are stratified into seven arms using the FUSCC 484-gene NGS panel testing and IHC subtyping. Abbreviations: mTNBC, metastatic triple-negative breast cancer; NGS, next-generation sequencing; IHC, immunohistochemistry; FUSCC, Fudan University Shanghai Cancer Center; LAR, luminal androgen receptor; IM, immunomodulatory; BLIS, basal-like immune-suppressed; MES, mesenchymal-like; n, number; AR, androgen receptor; PD-1, programmed cell death-1; PARPi, poly ADP-ribose polymerase inhibitor; VEGF, vascular endothelial growth factor; mTORi, mammalian target of rapamycin inhibitors. Table 2. Patient characteristics in the FUTURE trial. Table 3. Summary of treatment efficacy of TNBC in the FUTURE trial Citation Format: Zhi-Ming Shao, Zhong-Hua Wang, Yi-Zhou Jiang, Yin Liu, Xiu-Zhi Zhu, Yi Xiao, Song-Yang Wu, Wen-Jia Zuo, Qiang Yu, A-Yong Cao, Jun-Jie Li, Ke-Da Yu, Guang-Yu Liu, Jiong Wu, Tao Sun, Jiuwei Cui, Zheng Lv, Hui-Ping Li, Xiao-Yu Zhu. Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: a multicenter, phase 2, umbrella, FUTURE trial [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr OT3-27-01.

Article The Mechanism of Triacetyl Andrographolide in Inhibiting Proliferation of Pulmonary Artery Smooth Muscle Cells Zhe Wang 1,#, Yi-Xuan Zhang 2,#, Jun-Zhuo Shi 1,#, Chen-Chen Wang 1, Meng-Qi Zhang 1, Yi Yan 3, Yan-Ran Wang 1, Lu-Ling Zhao 1, Jie-Jian Kou 4, Qing-Hui Zhao 5, Xin-Mei Xie 1, Yang-Yang He 1,2, Jun-Ke Song 6,*, Guang Han 1,7,*, and Xiao-Bin Pang 1,2,* 1 School of Pharmacy, Henan University, Kaifeng 475004, China 2 Department of Anesthesiology, Huaihe Hospital of Henan University, Kaifeng 475004, China 3 Heart Center and Shanghai Institute of Pediatric Congenital Heart Disease, Shanghai Children's Medical Center, National Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200217, China 4 Department of Pharmacy, Huaihe Hospital of Henan University, Kaifeng 475004, China 5 Institute of Physical Culture, Huanghuai University, Zhumadian 463000, China 6 Beijing Key Laboratory of Drug Targets Identification and Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China 7 Henan Province Engineering Research Center of High Value Utilization to Natural Medical Resource in Yellow River Basin, Kaifeng 475004, China. * Correspondence: smilejunke@imm.ac.cn (Jun-Ke Song); hang@henu.edu.cn ( Guang Han); pxb@vip.henu.edu.cn ( Xiao-Bin Pang) Received: 17 April 2023 Accepted: 27 July 2023 Abstract: This study examines the impact of triacetyl-diacyllactone (ADA) on the proliferation and migration of pulmonary artery smooth muscle cells (PASMCs) and elucidates its underlying mechanism. PASMCs derived from SD rats were cultured in vitro and randomly divided into four groups: control group, administration group, model group, and model administration group. The appropriate concentration of ADA for intervention was determined using the MTT assay. The proliferation ability of PASMCs in each group was assessed using the EdU assay. The migration ability of PASMCs in each group was evaluated using the Scratch wound healing assay and Transwell assay. Western blot analysis was performed to determine the protein expression levels of BMPR2, PCNA, and TGF-β1, as well as the phosphorylation levels of SMAD1 and SMAD2/3 in PASMCs from each group. Results show that at a concentration of 5 µmol/L, ADA did not impact the cell activity of PASMCs and instead exerted inhibitory effects on both the proliferation and migration of PASMCs induced by PDGF-BB. PDGF-BB was found to upregulate the expression levels of PCNA and TGF-β1, while downregulating the expression of BMPR2. Furthermore, PDGF-BB led to enhanced protein phosphorylation of SMAD1 and SMAD2/3. However, following ADA intervention, the expression levels of PCNA and TGF-β1 decreased, while the expression of BMPR2 increased. Additionally, protein phosphorylation of SMAD1 and SMAD2/3 decreased. Therefore, ADA can hinder the proliferation and migration of PASMCs induced by PDGF-BB, as well as suppress the upregulation of PCNA and TGF-β1 caused by PDGF-BB. Furthermore, the downregulation of BMPR2 may be associated with the inhibition of SMAD1 and SMAD2/3 signaling pathways.

Introdução: O câncer é definido como uma proliferação descontrolada de células malignas em um hospedeiro e considerado uma das principais causas de morte em todo o mundo. No Brasil, o câncer colorretal é a segunda causa de morte mais comum entre mulheres e a terceira mais prevalente em homens. Muitas estratégias têm sido estudadas para auxiliar o tratamento antineoplásico. Dentro desse contexto, a ingestão de probióticos, representa uma nova opção terapêutica relevante no âmbito da nutrição. Objetivo: Realizar uma revisão sobre o uso dos probióticos no tratamento de pacientes com câncer colorretal. Material e Método: Trata-se de uma revisão realizada em 2018, utilizando-se 10 artigos, pesquisados nas bases indexadas BVS e PubMed e na ferramenta de pesquisa Google acadêmico. A pesquisa incluiu artigos em português e inglês publicados no período de 2010 a 2017. Resultados: O uso de probióticos demonstrou trazer efeitos positivos ao tratamento de pacientes com câncer colorretal, trazendo benefícios como: a diminuição de enterobactérias e enterococos, melhora na modulação da imunidade local, melhora dos sintomas intestinais, recuperação da função intestinal, entre outros. Conclusão: Conclui-se que apesar dos resultados positivos observados, há a necessidade de futuros estudos de longa duração para elucidar melhor essa relação.Descritores: Neoplasias Colorretais; Nutrientes; Probióticos.ReferênciasKahouli I, Malhotra M, Westfall S, Alaoui-Jamali MA, Prakash S. Design and validation of an orally administrated active L. fermentum-L. acidophilus probiotic formulation using colorectal cancer Apc Min/+ mouse model. Appl Microbiol Biotechnol. 2017;101(5):1999-2019.Oliveira RC, Rêgo MAV. Mortality risck of colorectal câncer in Brazil from 1980 to 2013. Arq Gastroenterol 2016;53(2)76-83.Instituto Nacional de Câncer (INCA). Tipos de câncer: colorretal. Rio de Janeiro: INCA; 2018.Instituto Nacional de Câncer (INCA). Estimativa 2016: incidência de Câncer no Brasil. Rio de Janeiro: INCA; 2016.Brasil. Ministério da Saúde. Departamento de Informática do SUS (DATASUS). Painel de Monitoramento da Mortalidade CID-10. Brasília; 2017.Corrêa RS, Pinto JRFE, Santos LV, Góis MC, Silva RP, Silva HM. Rectal cancer survival in a Brazilian Cancer Reference Unit. J Coloproctol. 2016;36:203-7.Oliveira AL, Aarestrupo FM. Avaliação nutricional e atividade inflamatória sistêmica de pacientes submetidos à suplementação com simbióticos. ABCD arq bras cir dig. 2012;25(3):147-53.Jacoby JT, Guzzon S, Rosech LFW, Mendes RH. Uso de pré, pró e simbióticos como coadjuvantes no tratamento do câncer colorretal. Clin Biomed Res. 2017;37(3):232-46.Gao Z, Guo B, Gao R, Zhu Q, Wu W, Qin H. Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer. Mol Med Rep. 2015;12(4):6119-27.Chaves PL, Gorini MI. Qualidade de vida do paciente com câncer colorretal em quimioterapia ambulatorial. Rev Gaucha Enferm. 2011;32(4):767-73.Barbosa, LRLS. Perfil nutricional de pacientes em pré-operatório eletivo para câncer colorretal [dissertação]. Belo Horizonte: Universidade Federal de Minas Gerais; 2011.Denipote FG, Trindade EBSM, Burini RC. Probióticos e Prebióticos na atenção primária ao câncer de cólon. Arq Gastroenterol. 2010;47(1):93-8.Machado FF, Lazzaretti RK, Poziomyck AK. Uso de prebióticos, probióticos e simbióticos nos pré e pós- operatórios do câncer colorretal: uma revisão. Rev bras cancerol. 2014;60(4):363-70.Correia MITD, Liboredo JC, Consoli MLD. The role of probiotics in gastrointestinal surgery. Nutrition. 2012;28(3):230-34.Zhang JW, Du P, Gao J, Yang BR, Fang WJ, Ying CM. Preoperative probiotics decrease postoperative infectious complications of colorectal cancer. Am J Med Sci. 2012;343(3):199-205.Liu Z, Qin H, Yang Z, Xia Y, Liu W, Yang J et al. Randomised clinical trial: the effects of perioperative probiotic treatment on barrier function and postoperative infectious complications in colorectal câncer surgery – a double-blind study. Aliment Pharmacol Ther. 2011;33(1):50-63.Yang Y, Xia Y, Chen H, Hong L, Feng J, Yang J et al. The effect of perioperative probiotics treatment for colorectal cancer: short-term outcomes of a randomized controlled trial. Oncotarget. 7(7);8432-40.Kotzampassi K, Stavrou G, Damoraki G, Georgitsi M, Basdanis G, Tsaousi G et al. A four-Probiotics regimen reduces postoperative complications after colorectal surgery: a randomized, double-blind, placebo-controlled study. World J Surg. 2015;39(11):2776-83.Lee JY, Chu SH, Jeon JY, Lee MK, Park JH, Lee DC et al. Effects of 12 weeks of probiotic supplementation on quality of life in colorectal cancer survivors: a double-blind, randomized, placebo-controlled trial. Dig Liver Dis. 2014;46(12):1126-32.Gianotti L, Morelli L, Galbiati F, Rocchetti S, Coppola S, Beneduce A. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol. 2010;16(2):167-75.Stephens JH, Hewett PJ. Clinical trial assessing VSL#3 for the treatment of anterior resection syndrome. ANZ J Surg. 2012;82(6):420-27.Xia Y, Yang Z, Chen HQ, Qin HL. Effect of bowel preparation with probiotics on intestinal barrier after surgery for colorectal cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 2010;13:528-31.Zhu D, Chen X, Wu J, Ju Y, Feng J, Lu G, et al. Effect of perioperative intestinal probiotics on intestinal flora and immune function in patients with colorectal cancer. Nan Fang Yi Ke Da Xue Xue Bao. 2012;32(8):1190-93.Derrien M, Van Hilckama Vlieg JE. Fate, activity, and impact of ingested bacteria within the human gut microbiota. Trends Microbiol. 2015;23(6):354-366.Gaudier E, Michel C, Segain JP, Cherbut C, Hoebler C. The VSL#3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfateinduced colitis or reinforce the mucus barrier in mice. J Nutr. 2005;135(12):2753-61.Mego M, Chovanec J, Vochyanova-Andrezalova I, Konkolovsky P, Mikulova M, Reckova M et al. Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study. Complement Ther Med. 2015;23(3):356-62.Yang Y, Xia Y, Chen H, Hong L, Feng J, Yang J et al. The effect of perioperative probiotics treatment for colorectal cancer: short-term outcomes of a randomized controlled trial. Oncotarget. 2016;7(7):8432-40.

Introdução: A transmissão SARS-CoV-2 de humano para humano pode ocorrer e o risco de propagação no ar durante os procedimentos odontológicos geradores de aerossóis permanece uma preocupação. Acredita-se que um enxaguatório bucal antimicrobiano pré-operacional reduza o número de micróbios orais. No entanto, a eficácia do enxaguatório bucal pré-procedimento na redução do número de microrganismos disseminados por meio do aerossol gerado por procedimentos odontológicos ainda não está clara. Objetivo: avaliar através de uma revisão de literatura o uso de enxaguantes bucais na redução da carga viral do SARS-CoV-2. Materiais e Método: O levantamento literário para esta pesquisa foi realizado no período de dezembro de 2019 a 10 de agosto de 2020 nas bases de dados Scielo e Medline/PubMed. Na estratégia de busca, foram utilizadas as palavras “SARS-CoV-2”, “2019-nCoV”, “COVID-19”, “Dentistry”, “Odontologia”, “Odontología”, “Mouthwashes”, “Antissépticos Bucais” e “Antisépticos Bucales”. Resultados: Uma busca sistematizada foi realizada, foram encontrados 661 artigos, após a realização da leitura criteriosa dos artigos completos foram selecionados 42 artigos. 88% dos estudos indicavam o uso de Peróxido de hidrogênio a 1%, 76% indicavam Povidine 0,2% e apenas 19% o uso da Clorexidina a 0,12%. Conclusão: Os estudos presentes na literatura apresentam divergências nas indicações e porcentagens dos enxaguantes indicados. Os protocolos clínicos devem ser avaliados para reduzir o risco de transmissão e proteger pacientes e profissionais.Descritores: Infecções por Coronavírus; Betacoronavirus; Odontologia; Antissépticos Bucais.ReferênciasGe ZY, Yang LM, Xia JJ, Fu XH, Zhang YZ. Possible aerosol transmission of COVID-19 and special precautions in dentistry. J Zhejiang Univ Sci B. 2020;21(5):361-68. Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020;12(1):9.Fallahi HR, Keyhan SO, Zandian D, Kim SG, Cheshmi B. Being a front-line dentist during the Covid-19 pandemic: a literature review. Maxillofac Plast Reconstr Surg. 2020;42(1):12.Yoon JG, Yoon J, Song JY, Yoon SY, Lim CS, Seong H, et al. Clinical Significance of a High SARS-CoV-2 Viral Load in the Saliva. J Korean Med Sci. 2020;35(20):e195.Alharbi A, Alharbi S, Alqaidi S. Guidelines for dental care provision during the COVID-19 pandemic. Saudi Dent J. 2020;32(4):181-86.Amato A, Caggiano M, Amato M, Moccia G, Capunzo M, De Caro F. Infection Control in Dental Practice During the COVID-19 Pandemic. Int J Environ Res Public Health. 2020;17(13):4769.Amorim, LM, Maske TT, Ferreira SH, Santos RB, Feldens CA, Kramer PF. New Post-COVID-19 Biosafety Protocols in Pediatric Dentistry. Pesqui Bras Odontopediatria Clín. Integr. 2020; 20(Suppl 1): e0117.Araya-Salas,C. Consideraciones para la Atención de Urgencia Odontológica y Medidas Preventivas para COVID-19 (SARS-CoV 2). Int. J. Odontostomat. 2020;14(3):268-70.Ather A, Patel B, Ruparel NB, Diogenes A, Hargreaves KM. Coronavirus Disease 19 (COVID-19): Implications for Clinical Dental Care. J Endod. 2020;46(5):584-95.Bahramian H, Gharib B, Baghalian A. COVID-19 Considerations in Pediatric Dentistry. JDR Clin Trans Res. 2020:2380084420941503.Bajaj N, Granwehr BP, Hanna EY, Chambers MS. Salivary detection of SARS-CoV-2 (COVID-19) and implications for oral health-care providers. Head Neck. 2020;42(7):1543-47.Barabari P, Moharamzadeh K. Novel Coronavirus (COVID-19) and Dentistry-A Comprehensive Review of Literature. Dent J (Basel). 2020;8(2):53.Barca I, Cordaro R, Kallaverja E, Ferragina F, Cristofaro MG. Management in oral and maxillofacial surgery during the COVID-19 pandemic: Our experience. Br J Oral Maxillofac Surg. 2020;58(6):687-91.Bhanushali P, Katge F, Deshpande S, Chimata VK, Shetty S, Pradhan D. COVID-19: Changing Trends and Its Impact on Future of Dentistry. Int J Dent. 2020;2020:8817424.Cabrera-Tasayco FDP, Rivera-Carhuavilca JM, Atoche-Socola KJ, Pena-Soto C, Arriola-Guillen LE. Biosafety measures at the dental office after the appearance of COVID-19: A systematic review. Disaster Med Public Health Prep. 2020:1-16. Carrouel F, Conte MP, Fisher J, et al. COVID-19: A Recommendation to Examine the Effect of Mouthrinses with beta-Cyclodextrin Combined with Citrox in Preventing Infection and Progression. J Clin Med. 2020;9(4):1126.Chen W, Wang Q, Li YQ, Yu HL, Xia YY, Zhang ML, et al. [Early containment strategies and core measures for prevention and control of novel coronavirus pneumonia in China]. Zhonghua Yu Fang Yi Xue Za Zhi. 2020;54(3):239-44.Duruk G, Gumusboga ZS, Colak C. Investigation of Turkish dentists' clinical attitudes and behaviors towards the COVID-19 pandemic: a survey study. Braz Oral Res. 2020;34:e054.Baghizadeh Fini M. What dentists need to know about COVID-19. Oral Oncol. 2020;105:104741.Guiñez-Coelho, M. Impacto del COVID-19 (SARS-CoV-2) a Nivel Mundial, Implicancias y Medidas Preventivas en la Práctica Dental y sus Consecuencias Psicológicas en los Pacientes. Int. J. Odontostomat. 2020;14(3):271-78.Guo Y, Jing Y, Wang Y, To A, Du S, Wang L,et al. Control of SARS-CoV-2 transmission in orthodontic practice. Am J Orthod Dentofacial Orthop. 2020;S0889-5406(20):30307-3.Gurzawska-Comis K, Becker K, Brunello G, Gurzawska A, Schwarz F. Recommendations for Dental Care during COVID-19 Pandemic. J Clin Med. 2020;9(6):1833.Ilyas N, Agel M, Mitchell J, Sood S. COVID-19 pandemic: the first wave - an audit and guidance for paediatric dentistry. Br Dent J. 2020; 228(12):927-3.Jamal M, Shah M, Almarzooqi SH, Aber H, Khawaja S, El Abed, et al. Overview of transnational recommendations for COVID-19 transmission control in dental care settings. Oral Dis. 2020.10.1111/odi.13431.Jotz GP, Voegels RL, Bento RF. Otorhinolaryngologists and Coronavirus Disease 2019 (COVID-19). Int. Arch. Otorhinolaryngol. 2020;24(2):125-28.Kerawala C, Riva F. Aerosol-generating procedures in head and neck surgery - can we improve practice after COVID-19? Br J Oral Maxillofac Surg. 2020;58(6):704-7.Koutras S, Govender S, Wood NH, Motloba PD. COVID-19 pandemic and the dental practice. S. Afr. dent. j. 2020;75(3):119-25. Lo Giudice R. The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2) in Dentistry. Management of Biological Risk in Dental Practice. Int J Environ Res Public Health. 2020;17(9):3067.Long RH, Ward TD, Pruett ME, Coleman JF, Plaisance MC, Jr. Modifications of emergency dental clinic protocols to combat COVID-19 transmission. Spec Care Dentist. 2020;40(3):219-26.Martins-Chaves RR, Gomes CC, Gomez RS. Immunocompromised patients and coronavirus disease 2019: a review and recommendations for dental health care. Braz Oral Res. 2020;34:e048.Naqvi K, Mubeen SM, Ali Shah SM. Challenges in providing oral and dental health services in COVID-19 pandemic. J Pak Med Assoc. 2020;70(Suppl 3)(5):S113-17.Passarelli PC, Rella E, Manicone PF, Garcia-Godoy F, D'Addona A. The impact of the COVID-19 infection in dentistry. Exp Biol Med (Maywood). 2020;245(11):940-44.Patil S, Moafa IH, Bhandi S, Jafer MA, Khan SS, Khan S,et al. Dental care and personal protective measures for dentists and non-dental health care workers. Dis Mon. 2020;101056.Peditto M, Scapellato S, Marciano A, Costa P, Oteri G. Dentistry during the COVID-19 Epidemic: An Italian Workflow for the Management of Dental Practice. Int J Environ Res Public Health. 2020;17(9):3325.Romero MR. Guía de buenas prácticas en Odontología para Uruguay durante la pandemia Covid-19. Odontoestomatología. 2020;22, 22(Supl 1):25-37.Sales PH, Sales PL, Da Hora Sales ML. COVID-2019. How to decrease the risk of infection in dental practice? Minerva Stomatol. 2020; 10.23736/S0026-4970.20.04372-1.Sarfaraz S, Shabbir J, Mudasser MA, Khurshid Z, Al-Quraini AAA,Abbasi MS, et al. Knowledge and Attitude of Dental Practitioners Related to Disinfection during the COVID-19 Pandemic. Healthcare (Basel). 2020;8(3):E232.Sigua-Rodríguez EA, Bernal-Pérez JL, Lanata-Flores AG, Sánchez-Romero C, Rodríguez-Chessa J, Haidar ZS, et al. COVID-19 y la Odontología: una revisión de las recomendaciones y perspectivas para latinoamérica. Int J Odontostomat. 2020;14(3):299-309.Siles-Garcia AA, Alzamora-Cepeda AG, Atoche-Socola KJ, Pena-Soto C, Arriola-Guillen LE. Biosafety for dental patients during dentistry care after COVID-19: A review of the literature. Disaster Med Public Health Prep. 2020:1-17.Turkistani KA. Precautions and recommendations for orthodontic settings during the COVID-19 outbreak: A review. Am J Orthod Dentofacial Orthop. 2020;158(2):175-81.Volgenant CMC, Persoon IF, de Ruijter RAG, de Soet JJH. Infection control in dental health care during and after the SARS-CoV-2 outbreak. Oral Dis. 2020;10.1111/odi.13408.Wu KY, Wu DT, Nguyen TT, Tran SD. COVID-19's impact on private practice and academic dentistry in North America. Oral Dis. 2020;10.1111/odi.13444.Zimmermann M, Nkenke E. Approaches to the management of patients in oral and maxillofacial surgery during COVID-19 pandemic. J Craniomaxillofac Surg. 2020;48(5):521-26.Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8.Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-73.Meng L, Hua F, Bian Z. Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine. J Dent Res. 2020;99(5):481-87.Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In vitro bactericidal and virucidal efficacy of povidone-iodine gargle/mouthwash against respiratory and oral tract pathogens. Infect Dis Ther. 2018;7(2):249-59.Lin L, Li TS. [Interpretation of "Guidelines for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Infection by the National Health Commission (Trial Version 5)"]. Zhonghua Yi Xue Za Zhi. 2020;100(0):E001.Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246-51.Martinez Lamas L, Diz Dios P, Perez Rodriguez MT, Pérez VDC, Alvargonzales JJC, Domínguez AML, et al. Is povidone iodine mouthwash effective against SARS-CoV-2? First in vivo tests. Oral Dis. 2020;10.1111/odi.13526.Marui VC, Souto MLS, Rovai ES, Romito GA, Chambrone L, Pannuti CM. Efficacy of preprocedural mouthrinses in the reduction of microorganisms in aerosol: A systematic review. J Am Dent Assoc. 2019;150(12):1015-26.e1.

Thesis (M.Phil.)--Hong Kong University of Science and Technology, 2004.
Includes bibliographical references (leaves 323-342). Also available in electronic version. Access restricted to campus users.